All In Biotech

Drug Trial Radar · NCT03398148

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,558 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,558

Actual

Start

Mar 7, 2018

Primary completion

Nov 9, 2022

Study completion May 11, 2023

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • risankizumab IVDrug

    risankizumab intravenous (IV) infusion

  • placebo for risankizumabDrug

    placebo for risankizumab

  • risankizumab SCDrug

    risankizumab subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreTime frame: Week 12
  2. Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreTime frame: Week 12

Locations

430 sites in 44 countries. Site status is shown where the registry gives one.

  • Southern California Res. Ctr. /ID# 169660

    Coronado, California

  • Hoag Memorial Hosp Presbyterian /ID# 218348

    Irvine, California

  • UC San Diego Health System /ID# 160452

    La Jolla, California

  • United Medical Doctors /ID# 158528

    Los Alamitos, California

  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 200931

    Los Angeles, California

  • UCSF Center for Colitis and Crohn's Disease /ID# 201210

    San Francisco, California

  • Cedars-Sinai Medical Center-West Hollywood /ID# 163851

    West Hollywood, California

  • Peak Gastroenterology Associates, PC /ID# 165841

    Colorado Springs, Colorado

  • Rocky Mountain Pediatric Gastroenterology /ID# 207174

    Lone Tree, Colorado

  • Medical Research Center of CT /ID# 160311

    Hamden, Connecticut

  • Yale Univ Digestive Diseases /ID# 213179

    New Haven, Connecticut

  • South Lake Pain Institute, Inc /ID# 162878

    Clermont, Florida

  • Ctr for Advanced Gastroenterol /ID# 202811

    Maitland, Florida

  • University of Miami /ID# 160471

    Miami, Florida

  • Coral Research Clinic /ID# 158584

    Miami, Florida

  • South Florida Research Ph I-IV, Inc. /ID# 161848

    Miami, Florida

  • Gastroenterology Group Naples /ID# 165212

    Naples, Florida

  • Advanced Research Institute, Inc /ID# 161938

    New Port Richey, Florida

  • Advent Health /ID# 160433

    Orlando, Florida

  • Endoscopic Research, Inc. /ID# 206711

    Orlando, Florida

  • Omega Research Group /ID# 203059

    Orlando, Florida

  • Lenus Research & Medical Group /ID# 169730

    Sweetwater, Florida

  • Clinical Research Trials of Florida, Inc. /ID# 201783

    Tampa, Florida

  • AdventHealth Tampa /ID# 170503

    Tampa, Florida

  • Gastroenterology Associates of Central Georgia, LLC /ID# 160523

    Macon, Georgia

  • Atlanta Gastroenterology Spec /ID# 161372

    Suwanee, Georgia

  • The University of Chicago Medical Center /ID# 160521

    Chicago, Illinois

  • DM Clinical Research/Southwest /ID# 165012

    Oak Lawn, Illinois

  • Indiana University /ID# 167252

    Indianapolis, Indiana

  • Univ Kansas Med Ctr /ID# 226602

    Kansas City, Kansas

  • Cotton-O'Neil Clinical Res Ctr /ID# 160412

    Topeka, Kansas

  • Robley Rex VA Medical Center /ID# 218648

    Louisville, Kentucky

  • Houma Digestive Health Special /ID# 158317

    Houma, Louisiana

  • Delricht Research /ID# 206815

    New Orleans, Louisiana

  • Nola Research Works, LLC /ID# 161368

    New Orleans, Louisiana

  • Louisana Research Center, LLC /ID# 201204

    Shreveport, Louisiana

  • Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164255

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 158524

    Ann Arbor, Michigan

  • Clin Res Inst of Michigan, LLC /ID# 160327

    Chesterfield, Michigan

  • Mayo Clinic - Rochester /ID# 200458

    Rochester, Minnesota

Showing 40 of 430 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.